Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-05-02 Board/Management Inform…
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis annonce le renforcement de son équipe de Direction
Board/Management Information Classification · 100% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces significant changes in the company's senior management team, specifically the appointment of a new Chief Operating Officer of Pharmaceutical Operations and Quality Assurance and a new Chief Financial Officer. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-05-02 French
Biophytis reçoit une notification du Nasdaq
Delisting Announcement Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces that Biophytis received a "Lettre de Notification" (Notice Letter) from Nasdaq regarding non-compliance with minimum equity requirements ($2,500,000). This is a specific, time-sensitive corporate action announcement related to stock exchange listing maintenance, not a comprehensive financial report (like 10-K or IR) or a standard earnings release (ER). It is a regulatory-related announcement concerning the company's listing status. While it could potentially fall under RNS (Regulatory Filings) as a general announcement, the content specifically deals with compliance and potential delisting risk, which is a critical corporate event announcement. Given the options, this type of specific, non-financial-result-focused regulatory update that is not a standard SEC form (like 10-K, DEF 14A, etc.) is best categorized as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was on raising capital to fix the issue, but the primary event is the notification itself. Since it is a press release announcing a formal notice from a stock exchange regarding listing compliance, RNS is the most appropriate general regulatory announcement fallback, as it doesn't fit the other specific categories like DIRS, DIV, or MANG. The document length (6104 chars) is substantial enough that it's not just a brief RPA, but a full announcement detailing the situation.
2023-04-28 French
Biophytis se conforme à nouveau aux exigences du NASDAQ en matière de cours d’achat minimum
Delisting Announcement Classification · 99% confidence The document is a press release dated April 19, 2023, announcing that Biophytis is once again in compliance with the Nasdaq minimum bid price requirement. This type of announcement, which communicates a specific, non-financial operational or regulatory compliance update (related to stock exchange listing rules), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a general corporate announcement. Since it is not a Director's Dealing (DIRS), a Dividend Notice (DIV), a Capital Change (CAP/SHA), or a specific legal/governance filing, the most appropriate fallback category is Regulatory Filings (RNS), as it pertains to compliance with a regulatory body (Nasdaq). The document length (5522 chars) is substantial enough that it is the primary communication, not just a brief announcement of another report.
2023-04-19 French
Biophytis annonce ses résultats financiers 2022 et ses perspectives 2023
Earnings Release Classification · 95% confidence The document is a press release from Biophytis announcing its 2022 financial results and 2023 outlook. It provides key financial highlights, a summary of operational achievements, and management commentary. While it contains financial data, it is an initial announcement of results rather than the full audited Annual Report (10-K) or a formal interim report (IR). According to the filing definitions, an initial announcement of financial results is classified as an Earnings Release (ER). FY 2022
2023-04-18 French
Résultats de l’Assemblée Générale Mixte du 17 avril 2023
AGM Information Classification · 99% confidence The document is titled "Résultats de l'Assemblée Générale Mixte du 17 avril 2023" (Results of the Combined General Meeting of April 17, 2023) and explicitly states that "l'ensemble des résolutions proposées par la Société... ont été approuvées à une large majorité." It details key outcomes like the reduction of the nominal share value and mentions that the voting results will be available later. This content directly relates to the official outcomes of a shareholder meeting. This aligns perfectly with the definition for AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). While it reports results, it is the primary communication about the AGM event itself, making AGM-R the most specific fit over DVA (which is strictly the declaration of voting results) or RPA (which is an announcement of a report publication).
2023-04-17 French
L’Assemblée Générale mixte se tiendra en seconde convocation le 17 avril 2023
AGM Information Classification · 98% confidence The document is a press release (Communiqué de presse) announcing that the Extraordinary General Meeting (Assemblée Générale Extraordinaire) scheduled for March 30, 2023, failed to meet the quorum requirement and is therefore adjourned. It explicitly states that a new joint general meeting (Assemblée Générale mixte) will be held on April 17, 2023, with the same agenda items (share consolidation, nominal value reduction, renewal of authorizations). This document is an announcement regarding the scheduling and status of a shareholder meeting, specifically dealing with the failure of the first call and the setting of the second call date. This aligns best with 'AGM Information' (AGM-R), as it directly concerns the logistics and rescheduling of the Annual General Meeting process.
2023-03-30 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.